Lake Street Capital upgraded shares of AxoGen Inc. (NASDAQ:AXGN) from a hold rating to a buy rating in a research note released on Tuesday morning. Lake Street Capital currently has $11.00 price objective on the stock, up from their prior price objective of $9.00.

Separately, Wedbush boosted their price target on AxoGen from $10.00 to $12.00 and gave the stock an outperform rating in a research note on Monday, November 7th.

AxoGen (NASDAQ:AXGN) traded up 2.89% during mid-day trading on Tuesday, hitting $8.90. The stock had a trading volume of 72,846 shares. The company has a 50-day moving average of $8.65 and a 200-day moving average of $7.62. The stock’s market cap is $292.79 million. AxoGen has a 12-month low of $4.52 and a 12-month high of $9.88.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). AxoGen had a negative return on equity of 292.94% and a negative net margin of 33.02%. On average, analysts anticipate that AxoGen will post ($0.38) earnings per share for the current fiscal year.

In other news, VP John P. Engels acquired 4,000 shares of the business’s stock in a transaction on Friday, October 7th. The shares were purchased at an average price of $7.50 per share, for a total transaction of $30,000.00. Following the completion of the purchase, the vice president now directly owns 98,425 shares of the company’s stock, valued at approximately $738,187.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amy Mcbride Wendell acquired 13,333 shares of the business’s stock in a transaction on Friday, October 7th. The shares were purchased at an average price of $7.50 per share, for a total transaction of $99,997.50. Following the purchase, the director now directly owns 13,333 shares of the company’s stock, valued at $99,997.50. The disclosure for this purchase can be found here. Company insiders own 9.33% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors boosted its stake in shares of AxoGen by 1,049.1% in the second quarter. BlackRock Fund Advisors now owns 634,132 shares of the company’s stock valued at $4,363,000 after buying an additional 578,948 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of AxoGen by 61.5% in the second quarter. Vanguard Group Inc. now owns 775,448 shares of the company’s stock valued at $5,335,000 after buying an additional 295,294 shares during the last quarter. State Street Corp purchased a new stake in shares of AxoGen during the second quarter valued at about $1,885,000. Summit Partners Public Asset Management LLC purchased a new stake in shares of AxoGen during the third quarter valued at about $2,376,000. Finally, Waddell & Reed Financial Inc. purchased a new stake in shares of AxoGen during the second quarter valued at about $1,371,000. Hedge funds and other institutional investors own 54.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/23/axogen-inc-axgn-upgraded-by-lake-street-capital-to-buy.html.

5 Day Chart for NASDAQ:AXGN

Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.